The funding, which also saw participation from Oslo-based DNV-GL and existing angel investors, will fuel further development of uMotif’s patient-centric and decentralised approach to clinical studies and enable expansion into new study types and more high-demand territories. Helping get much-needed, and at times life-saving, therapies to patients faster.
“We’re excited to help our customers implement patient-centred research designs by using the uMotif platform to capture high-quality data. This new funding will rapidly accelerate our development and will ultimately help our customers to get new therapies to patients faster.” – Bruce Hellman, CEO and Co-Founder of uMotif
Life sciences companies are increasingly embracing decentralised and virtual study designs – where patient consent and data is captured using their own devices from wherever they are located. This is in stark contrast to the centralised, inconvenient and complex studies in which patients have to go to a site, such as a hospital, to submit their data. A trend that has been further driven by COVID-19.
UMotif powers innovative decentralised and patient-centric approaches that increase patient engagement, improving the chances of the study’s success, reducing the burden on participants, and helping to reach new patient populations and increase study diversity.
“Now more than ever, having access to reliable patient data during clinical trials is crucial. uMotif’s platform is built with patients in mind; designed to help academics, researchers and healthcare professionals to capture the best quality data in a way that suits the participants. It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the speed and efficiency with which therapies can reach and help millions of patients.” – Dr. Andrew Elder, Deputy Managing Partner at AlbionVC
UMotif’s robust and scalable cloud-based platform is trusted by the world’s leading pharmaceutical and biotech companies to capture clinical research data, and its strengths lie in the way it works with and keeps thousands of research participants engaged. With studies taking place in 26 countries from clinical to real-world settings, and across more than 25 therapeutic areas – from dermatology and rare disease to oncology and cardiology, uMotif’s focus is to foster a highly engaging patient experience to capture larger volumes of higher quality data.
New funding will further enhance uMotif’s highly configurable software platform to support existing studies and support new study designs. With a customer base spanning Europe and the US, the investment will drive continued commercial growth and enable further geographical expansion.
“Healthcare is dependent on digital transformation if it is to move towards being a more sustainable sector. uMotif has developed a digital platform that can support new models of clinical trials while also ensuring that the patient voice is heard. We have been impressed with the platform and the management team at uMotif who are responsive to customer and patient needs and passionate about making a difference.” – Kaare Helle, Venture Director at DNV GL